Heather Nicole Johnson, FNP-C Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 13486 Springhill Ct Apt Suite, Winnebago, IL 61088 Phone: 815-262-8995 |
Jennifer L. Dinges, NP Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 102 Landmark Dr, Winnebago, IL 61088 Phone: 815-971-2000 |
News Archive
While the most prevalent focus of February is on Valentine's sweethearts, parents are well advised to also focus on the proverbial sweet tooth - particularly when it comes to their children. That's because February is National Children's Dental Health Month, an ideal time - according to Health Net, Inc. - for moms and dads to make sure that sugary snacks, as well as lax dental hygiene - aren't putting their kids at risk for tooth decay.
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
A rare and deadly form of breast cancer that often goes unrecognized by clinicians and patients alike is the focus of a new report from leading researchers. Inflammatory breast cancer (IBC) has made headlines as an unrecognized and misunderstood form of breast cancer. It has a younger age of onset, progresses rapidly, and has lower overall survival compared to other breast cancers.
Digimarc Corporation has licensed its mobile visual search software to New Jersey-based Catalent Pharma Solutions, a leading provider of innovative packaging solutions to the pharmaceutical, biotechnology, and consumer healthcare industries.
Population Genetics Technologies Ltd., creator of innovative methods for genetic analyses and biomarker discovery, has successfully completed a pilot study to prove that its GenomePooling™ method is sensitive and accurate enough to detect even small percentages of gene variants within cancer tissue. This validates the method's suitability for use in IntReALL 2010, the world's largest genetic analysis of acute lymphoblastic leukaemia (ALL) relapse cases. ALL is the most common childhood malignant disease.
› Verified 6 days ago